Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,167
archived clinical trials in
Liver Cancer

MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated:  9/3/2015
Central Illinois Hematology Oncology Center
1608
mi
from 91732
Springfield, IL
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated: 9/3/2015
Central Illinois Hematology Oncology Center
1608
mi
from 91732
Springfield, IL
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated:  9/3/2015
Southern Illinois University
1608
mi
from 91732
Springfield, IL
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated: 9/3/2015
Southern Illinois University
1608
mi
from 91732
Springfield, IL
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated:  9/3/2015
Northern Indiana Cancer Research Consortium
1799
mi
from 91732
South Bend, IN
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated: 9/3/2015
Northern Indiana Cancer Research Consortium
1799
mi
from 91732
South Bend, IN
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated:  9/3/2015
University of Maryland Greenebaum Cancer Center
2301
mi
from 91732
Baltimore, MD
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated: 9/3/2015
University of Maryland Greenebaum Cancer Center
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated:  9/3/2015
Oncology Care Associates, PLLC
1790
mi
from 91732
Saint Joseph, MI
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated: 9/3/2015
Oncology Care Associates, PLLC
1790
mi
from 91732
Saint Joseph, MI
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated:  9/3/2015
Saint John's Mercy Medical Center
1573
mi
from 91732
Saint Louis, MO
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated: 9/3/2015
Saint John's Mercy Medical Center
1573
mi
from 91732
Saint Louis, MO
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated:  9/3/2015
The Ohio State University Comprehensive Cancer Center
1959
mi
from 91732
Columbus, OH
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated: 9/3/2015
The Ohio State University Comprehensive Cancer Center
1959
mi
from 91732
Columbus, OH
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated:  9/3/2015
Penn State Milton S. Hershey Medical Center
2296
mi
from 91732
Hershey, PA
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated: 9/3/2015
Penn State Milton S. Hershey Medical Center
2296
mi
from 91732
Hershey, PA
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated:  9/3/2015
University of Pittsburgh
2121
mi
from 91732
Pittsburgh, PA
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated: 9/3/2015
University of Pittsburgh
2121
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated:  9/3/2015
City of Hope Medical Center
4
mi
from 91732
Duarte, CA
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated: 9/3/2015
City of Hope Medical Center
4
mi
from 91732
Duarte, CA
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated:  9/3/2015
U.S.C./Norris Comprehensive Cancer Center
11
mi
from 91732
Los Angeles, CA
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated: 9/3/2015
U.S.C./Norris Comprehensive Cancer Center
11
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated:  9/3/2015
University of California-Davis Comprehensive Cancer Ctr
363
mi
from 91732
Sacramento, CA
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated: 9/3/2015
University of California-Davis Comprehensive Cancer Ctr
363
mi
from 91732
Sacramento, CA
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated:  9/3/2015
NorthShore University HealthSystem-Evanston Hospital
1728
mi
from 91732
Evanston, IL
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated: 9/3/2015
NorthShore University HealthSystem-Evanston Hospital
1728
mi
from 91732
Evanston, IL
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated:  9/3/2015
Loyola University Medical Center
1719
mi
from 91732
Maywood, IL
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated: 9/3/2015
Loyola University Medical Center
1719
mi
from 91732
Maywood, IL
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated:  9/3/2015
Fort Wayne Medical Oncology and Hematology Inc-Parkview
1853
mi
from 91732
Fort Wayne, IN
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated: 9/3/2015
Fort Wayne Medical Oncology and Hematology Inc-Parkview
1853
mi
from 91732
Fort Wayne, IN
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated:  9/3/2015
University of Michigan
1932
mi
from 91732
Ann Arbor, MI
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated: 9/3/2015
University of Michigan
1932
mi
from 91732
Ann Arbor, MI
Click here to add this to my saved trials
Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor)
Phase I Dose Escalation Trial of External Beam Radiation and Cyberknife Radiosurgery Boost With Concurrent Capecitabine for Hilar Cholangiocarcinoma (Klatskin Tumor)
Status: Enrolling
Updated:  9/9/2015
University of California at San Francisco
356
mi
from 91732
San Francisco, CA
Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor)
Phase I Dose Escalation Trial of External Beam Radiation and Cyberknife Radiosurgery Boost With Concurrent Capecitabine for Hilar Cholangiocarcinoma (Klatskin Tumor)
Status: Enrolling
Updated: 9/9/2015
University of California at San Francisco
356
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer
Phase II Study of Drug-eluting Irinotecan Beads (DEBIRI) in Refractory Metastatic Colorectal Cancer With Liver-only or Liver-predominant Disease
Status: Enrolling
Updated:  9/10/2015
Fox Chase Cancer Center
2379
mi
from 91732
Philadelphia, PA
Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer
Phase II Study of Drug-eluting Irinotecan Beads (DEBIRI) in Refractory Metastatic Colorectal Cancer With Liver-only or Liver-predominant Disease
Status: Enrolling
Updated: 9/10/2015
Fox Chase Cancer Center
2379
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
Status: Enrolling
Updated:  9/21/2015
Massachusetts General Hospital
2578
mi
from 91732
Boston, MA
A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
Status: Enrolling
Updated: 9/21/2015
Massachusetts General Hospital
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
Status: Enrolling
Updated:  9/21/2015
Dana-Farber Cancer Institute
2578
mi
from 91732
Boston, MA
A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
Status: Enrolling
Updated: 9/21/2015
Dana-Farber Cancer Institute
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
Status: Enrolling
Updated:  9/21/2015
Brigham and Women's Hosp
2578
mi
from 91732
Boston, MA
A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
Status: Enrolling
Updated: 9/21/2015
Brigham and Women's Hosp
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
24hr Imaging Of HCC After EOVIST
Pilot Study of Delayed, 24 Hour Imaging of Hepatocellular Carcinoma Following the Administration of the Hepatobiliary MRI Contrast Agent Gadolinium Ethoxybenzyl Dimeglumine (Eovist)
Status: Enrolling
Updated:  9/22/2015
Massachusetts General Hospital
2578
mi
from 91732
Boston, MA
24hr Imaging Of HCC After EOVIST
Pilot Study of Delayed, 24 Hour Imaging of Hepatocellular Carcinoma Following the Administration of the Hepatobiliary MRI Contrast Agent Gadolinium Ethoxybenzyl Dimeglumine (Eovist)
Status: Enrolling
Updated: 9/22/2015
Massachusetts General Hospital
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
Agajanian Institute Of Hematology And Oncology
11
mi
from 91732
Downey, CA
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
Agajanian Institute Of Hematology And Oncology
11
mi
from 91732
Downey, CA
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
Sharp Clinical Oncology Research
101
mi
from 91732
San Diego, CA
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
Sharp Clinical Oncology Research
101
mi
from 91732
San Diego, CA
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
James Graham Brown Cancer Center
1813
mi
from 91732
Louisville, KY
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
James Graham Brown Cancer Center
1813
mi
from 91732
Louisville, KY
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
3912 Taubman Center
1932
mi
from 91732
Ann Arbor, MI
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
3912 Taubman Center
1932
mi
from 91732
Ann Arbor, MI
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
Mayo Clinic Arizona
356
mi
from 91732
Scottsdale, AZ
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
Mayo Clinic Arizona
356
mi
from 91732
Scottsdale, AZ
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
Univ Of Ark For Med Sci
1463
mi
from 91732
Little Rock, AR
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
Univ Of Ark For Med Sci
1463
mi
from 91732
Little Rock, AR
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
Va Ct Healthcare System
2485
mi
from 91732
West Haven, CT
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
Va Ct Healthcare System
2485
mi
from 91732
West Haven, CT
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
Medical Specialists Of Palm Beaches
2300
mi
from 91732
Lake Worth, FL
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
Medical Specialists Of Palm Beaches
2300
mi
from 91732
Lake Worth, FL
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
Karmanos Cancer Institute
1966
mi
from 91732
Detroit, MI
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
Karmanos Cancer Institute
1966
mi
from 91732
Detroit, MI
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
Thomas Jefferson University
2375
mi
from 91732
Philadelphia, PA
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
Thomas Jefferson University
2375
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
Mcguire Dvamc
2265
mi
from 91732
Richmond, VA
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
Mcguire Dvamc
2265
mi
from 91732
Richmond, VA
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
University of Wisconsin
1654
mi
from 91732
Madison, WI
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
University of Wisconsin
1654
mi
from 91732
Madison, WI
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
Local Institution
6113
mi
from 91732
Caba,
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
Local Institution
6113
mi
from 91732
Caba,
Click here to add this to my saved trials
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated:  9/23/2015
City of Hope National Medical Center
5
mi
from 91732
Duarte, CA
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated: 9/23/2015
City of Hope National Medical Center
5
mi
from 91732
Duarte, CA
Click here to add this to my saved trials
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated:  9/23/2015
Harbor-Ucla Medical Center
24
mi
from 91732
Los Angeles, CA
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated: 9/23/2015
Harbor-Ucla Medical Center
24
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated:  9/23/2015
Christiana Care Health Services, Inc
2347
mi
from 91732
Newark, DE
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated: 9/23/2015
Christiana Care Health Services, Inc
2347
mi
from 91732
Newark, DE
Click here to add this to my saved trials
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated:  9/23/2015
University of Miami Miller School of Medicine
2320
mi
from 91732
Miami, FL
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated: 9/23/2015
University of Miami Miller School of Medicine
2320
mi
from 91732
Miami, FL
Click here to add this to my saved trials
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated:  9/23/2015
Northwestern University Feinberg School of Medicine
1730
mi
from 91732
Chicago, IL
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated: 9/23/2015
Northwestern University Feinberg School of Medicine
1730
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated:  9/23/2015
University of Chicago
1730
mi
from 91732
Chicago, IL
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated: 9/23/2015
University of Chicago
1730
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated:  9/23/2015
University of Iowa Hospitals and Clinics
1528
mi
from 91732
Iowa City, IA
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated: 9/23/2015
University of Iowa Hospitals and Clinics
1528
mi
from 91732
Iowa City, IA
Click here to add this to my saved trials
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated:  9/23/2015
Wayne State University
1965
mi
from 91732
Detroit, MI
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated: 9/23/2015
Wayne State University
1965
mi
from 91732
Detroit, MI
Click here to add this to my saved trials
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated:  9/23/2015
The Cancer Center, Hackensack University Medical Center
2430
mi
from 91732
Hackensack, NJ
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated: 9/23/2015
The Cancer Center, Hackensack University Medical Center
2430
mi
from 91732
Hackensack, NJ
Click here to add this to my saved trials
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated:  9/23/2015
Duke Univ Med Ctr
2203
mi
from 91732
Durham, NC
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated: 9/23/2015
Duke Univ Med Ctr
2203
mi
from 91732
Durham, NC
Click here to add this to my saved trials
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated:  9/23/2015
Penn State Milton S. Hershey Medical Center
2296
mi
from 91732
Hershey, PA
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated: 9/23/2015
Penn State Milton S. Hershey Medical Center
2296
mi
from 91732
Hershey, PA
Click here to add this to my saved trials
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated:  9/23/2015
Albert Einstein Cancer Center
2376
mi
from 91732
Philadelphia, PA
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated: 9/23/2015
Albert Einstein Cancer Center
2376
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated:  9/23/2015
University of Texas Southwestern
1221
mi
from 91732
Dallas, TX
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated: 9/23/2015
University of Texas Southwestern
1221
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated:  9/23/2015
M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated: 9/23/2015
M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated:  9/23/2015
Medical College of Wisconsin
1729
mi
from 91732
Milwaukee, WI
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated: 9/23/2015
Medical College of Wisconsin
1729
mi
from 91732
Milwaukee, WI
Click here to add this to my saved trials